Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -344K | -644K | -630K | -802K | -554K |
| EBITDA | -344K | -40K | -598K | -802K | -611K |
| Net Income | -56K | -789K | -734K | -1M | -663K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0111
+0.00% today
1Y Change
-83.72%
Window
Jun 23, 2025 → May 27, 2026
Coverage: 197 bars · Jun 23, 2025 → May 27, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Qrons Inc. (QRON) is a Healthcare stock with a market cap of $199.80K and listed on OTC. The stock last traded around $0.01 and down 83.7% across the available one-year price window (Jun 23, 2025 → May 27, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +93.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +93.1%, free cash flow +10.0% with operating margin 0.0% and ROIC 236.1%. Stock Foundry combines QRON price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QRON
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QRON Max Drawdown
-84.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QRON and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$663.0K
+37.9% YoY
Free Cash Flow
-$220.4K
-79.8% YoY
Revenue Growth
+0.0%
EPS Growth
+93.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -344K | -644K | -630K | -802K | -554K |
| EBITDA | -344K | -40K | -598K | -802K | -611K |
| Net Income | -56K | -789K | -734K | -1M | -663K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 659 | 420 | 3K | 35K | 58K |
| Total Assets | 659 | 420 | 3K | 35K | 58K |
| Total Liabilities | 446K | 1M | 1M | 1M | 752K |
| Shareholder Equity | -445K | -1M | -1M | -1M | -694K |
| Total Debt | 296K | 352K | 294K | 217K | 119K |
| Net Debt | 295K | 351K | 291K | 182K | 61K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
220K
-79.8% YoY
Capital Expenditures
3
+200.0% YoY
Free Cash Flow
220K
-79.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
5.8%
Debt / Equity
-0.67x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.